Therapeutic targeting of the tumor microenvironment

Cancer Cell

Volumn 7, Issue 6, 2005, Pages 513-520

  Joyce, Johanna A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; CILENGITIDE; COMBRETASTATIN A4; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; ENZASTAURIN; IMATINIB; LENALIDOMIDE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PI 88; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SIBROTUZUMAB; SUNITINIB; SURAMIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB; VOLOCIXIMAB;

BASEMENT MEMBRANE; BLADDER CANCER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; CHRONIC INFLAMMATION; CHRONIC PANCREATITIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLIOMA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INNATE IMMUNITY; LIVER CANCER; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MICROENVIRONMENT; NONHUMAN; PANCREAS CANCER; PERICYTE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH CANCER; STROMA; TARGET CELL; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 20444412646     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.05.024     Document Type: Short Survey

References (99)

1. M.G. Achen, B.K. McColl, and S.A. Stacker Focus on lymphangiogenesis in tumor metastasis Cancer Cell 7 2005 121 127
2. M. Allinen, R. Beroukhim, L. Cai, C. Brennan, J. Lahti-Domenici, H. Huang, D. Porter, M. Hu, L. Chin, and A. Richardson Molecular characterization of the tumor microenvironment in breast cancer Cancer Cell 6 2004 17 32
3. F. Balkwill Cancer and the chemokine network Nat. Rev. Cancer 4 2004 540 550
4. F. Balkwill, K.A. Charles, and A. Mantovani Smoldering and polarized inflammation in the initiation and promotion of malignant disease Cancer Cell 7 2005 211 217
5. R. Benezra, S. Rafii, and D. Lyden The Id proteins and angiogenesis Oncogene 20 2001 8334 8341
6. L.E. Benjamin, D. Golijanin, A. Itin, D. Pode, and E. Keshet Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J. Clin. Invest. 103 1999 159 165
7. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295
8. N.A. Bhowmick, A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, S. Shappell, M.K. Washington, E.G. Neilson, and H.L. Moses TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 303 2004 848 851
9. N.A. Bhowmick, E.G. Neilson, and H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature 432 2004 332 337
10. M. Bissell, and D. Radisky Putting tumors in context Nat. Rev. Cancer 1 2001 46 54
11. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, and A. Lanas Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N. Engl. J. Med. 352 2005 1092 1102
12. R. Cao, M.A. Bjorndahl, P. Religa, S. Clasper, S. Garvin, D. Galter, B. Meister, F. Ikomi, P. Tritsaris, and S. Dissing PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis Cancer Cell 6 2004 333 345
13. P. Carmeliet Angiogenesis in health and disease Nat. Med. 9 2003 653 660
14. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
15. A.F. Chambers, A.C. Groom, and I.C. MacDonald Dissemination and growth of cancer cells in metastatic sites Nat. Rev. Cancer 2 2002 563 572
16. J.D. Cheng, R.L. Dunbrack Jr., M. Valianou, A. Rogatko, R.K. Alpaugh, and L.M. Weiner Promotion of tumor growth by murin fibroblast activation protein, a serine protease, in an animal model Cancer Res. 62 2002 4767 4772
17. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
18. L.M. Coussens, C.L. Tinkle, D. Hanahan, and Z. Werb MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis Cell 103 2000 481 490
19. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 295 2002 2387 2392
20. J.S. Damiano, A.E. Cress, L.A. Hazlehurst, A.A. Shtil, and W.S. Dalton Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines Blood 93 1999 1658 1667
21. M. De Palma, M.A. Venneri, C. Roca, and L. Naldini Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells Nat. Med. 9 2003 789 795
22. G. Dranoff Cytokines in cancer pathogenesis and cancer therapy Nat. Rev. Cancer 4 2004 11 22
23. F. Fan, J.S. Wey, M.F. McCarty, A. Belcheva, W. Liu, T.W. Bauer, R.J. Somcio, Y. Wu, A. Hooper, D.J. Hicklin, and L.M. Ellis Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells Oncogene 24 2005 2647 2653
24. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400
25. I.J. Fidler The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited Nat. Rev. Cancer 3 2003 453 458
26. J. Folkman Tumor angiogenesis: Therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
27. J. Folkman, P. Hahnfeldt, and L. Hlatky Cancer: Looking outside the genome Nat. Rev. Mol. Cell Biol. 1 2000 76 79
28. G. Forni, H. Fujiwara, F. Martino, T. Hamaoka, C. Jemma, P. Caretto, and M. Giovarelli Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy Cancer Metastasis Rev. 7 1988 289 309
29. K. Garber Angiogenesis inhibitors suffer new setback Nat. Biotechnol. 20 2002 1067 1068
30. P. Garin-Chesa, L.J. Old, and W.J. Rettig Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers Proc. Natl. Acad. Sci. USA 87 1990 7235 7239
31. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J. Clin. Invest. 114 2004 623 633
32. W. Guo, and F.G. Giancotti Integrin signalling during tumour progression Nat. Rev. Mol. Cell Biol. 5 2004 816 826
33. Y. Hamano, M. Zeisberg, H. Sugimoto, J.C. Lively, Y. Maeshima, C. Yang, R.O. Hynes, Z. Werb, A. Sudhakar, and R. Kalluri Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin Cancer Cell 3 2003 589 601
34. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
35. N. Hayashi, and G.R. Cunha Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma Cancer Res. 51 1991 4924 4930
36. S.W. Hayward, Y. Wang, M. Cao, Y.K. Hom, B. Zhang, G.D. Grossfeld, D. Sudilovsky, and G.R. Cunha Malignant transformation in a nontumorigenic human prostatic epithelial cell line Cancer Res. 61 2001 8135 8142
37. Y. He, K. Kozaki, T. Karpanen, K. Koshikawa, S. Yla-Herttuala, T. Takahashi, and K. Alitalo Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling J. Natl. Cancer Inst. 94 2002 819 825
38. C.H. Heldin, K. Rubin, K. Pietras, and A. Ostman High interstitial fluid pressure - an obstacle in cancer therapy Nat. Rev. Cancer 4 2004 806 813
39. W. Hilbe, S. Dirnhofer, F. Oberwasserlechner, T. Schmid, E. Gunsilius, G. Hilbe, E. Woll, and C.M. Kahler CD133 positive endothelial progenitor cells contribute to the tumor vasculature in non-small cell lung cancer J. Clin. Pathol. 57 2004 965 969
40. R. Hildenbrand, G. Wolf, B. Bohme, U. Bleyl, and A. Steinborn Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue J. Leukoc. Biol. 66 1999 40 49
41. J.A. Hoffman, E. Giraudo, M. Singh, L. Zhang, M. Inoue, K. Porkka, D. Hanahan, and E. Ruoslahti Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma Cancer Cell 4 2003 383 391
42. J.D. Hood, and D.A. Cheresh Role of integrins in cell invasion and migration Nat. Rev. Cancer 2 2002 91 100
43. J. Huang, J.S. Frischer, A. Serur, A. Kadenhe, A. Yokoi, K.W. McCrudden, T. New, K. O'Toole, S. Zabski, and J.S. Rudge Regression of established tumors and metastases by potent vascular endothelial growth factor blockade Proc. Natl. Acad. Sci. USA 100 2003 7785 7790
44. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, and E. Holmgren Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
45. S.P. Hussain, L.J. Hofseth, and C.C. Harris Radical causes of cancer. Nat Rev Cancer 3, 276-285.Hynes, R.O. (2002). A reevaluation of integrins as regulators of angiogenesis Nat. Med. 8 2003 918 921
46. R.O. Hynes A reevaluation of integrins as regulators of angiogenesis Nat. Med. 8 2002 918 921
47. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy Nat. Med. 7 2001 987 989
48. R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62
49. H. Jin, and J. Varner Integrins: Roles in cancer development and as treatment targets Br. J. Cancer 90 2004 561 565
50. J.A. Joyce, P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti, and D. Hanahan Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis Cancer Cell 4 2003 393 403
51. J.A. Joyce, A. Baruch, K. Chehade, N. Meyer-Morse, E. Giraudo, F.Y. Tsai, D.C. Greenbaum, J.H. Hager, M. Bogyo, and D. Hanahan Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis Cancer Cell 5 2004 443 453
52. J.A. Joyce, C. Freeman, N. Meyer-Morse, C.F. Parish, and D. Hanahan A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer Oncogene 2005 000 000 in press
53. R. Kalluri Basement membranes: Structure, assembly and role in tumour angiogenesis Nat. Rev. Cancer 3 2003 422 433
54. M. Karin, Y. Yamamoto, and Q.M. Wang The IKK NF-kappa B system: A treasure trove for drug development Nat. Rev. Drug Discov. 3 2004 17 26
55. R. Kerbel, and J. Folkman Clinical translation of angiogenesis inhibitors Nat. Rev. Cancer 2 2002 727 739
56. C. Kuperwasser, T. Chavarria, M. Wu, G. Magrane, J.W. Gray, L. Carey, A. Richardson, and R.A. Weinberg Reconstruction of functionally normal and malignant human breast tissues in mice Proc. Natl. Acad. Sci. USA 101 2004 4966 4971
57. L.T. Lam, R.E. Davis, J. Pierce, M. Hepperle, Y. Xu, M. Hottelet, Y. Nong, D. Wen, J. Adams, L. Dang, and L.M. Staudt Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling Clin. Cancer Res. 11 2005 28 40
58. E. Lammerts, P. Roswall, C. Sundberg, P.J. Gotwals, V.E. Koteliansky, R.K. Reed, N.E. Heldin, and K. Rubin Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma Int. J. Cancer 102 2002 453 462
59. H. Li, W.L. Gerald, and R. Benezra Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade Cancer Res. 64 2004 6137 6143
60. E.Y. Lin, A.V. Nguyen, R.G. Russell, and J.W. Pollard Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy J. Exp. Med. 193 2001 727 740
61. D. Lyden, K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. Heissig, W. Marks, and L. Witte Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat. Med. 7 2001 1194 1201
62. H. Maeda, and T. Akaike Nitric oxide and oxygen radicals in infection, inflammation, and cancer Biochemistry (Mosc.) 63 1998 854 865
63. P.J. Morin Drug resistance and the microenvironment: Nature and nurture Drug Resist. Updat. 6 2003 169 172
64. A. Muller, B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, and S.N. Wagner Involvement of chemokine receptors in breast cancer metastasis Nature 410 2001 50 56
65. S.K. Muthuswamy, D. Li, S. Lelievre, M.J. Bissell, and J.S. Brugge ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini Nat. Cell Biol. 3 2001 785 792
66. P. Oh, Y. Li, J. Yu, E. Durr, K.M. Krasinska, L.A. Carver, J.E. Testa, and J.E. Schnitzer Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy Nature 429 2004 629 635
67. A.F. Olumi, G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium Cancer Res. 59 1999 5002 5011
68. A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 121 2005 335 348
69. M.A. Palladino, F.R. Bahjat, E.A. Theodorakis, and L.L. Moldawer Anti-TNF-alpha therapies: The next generation Nat. Rev. Drug Discov. 2 2003 736 746
70. M. Papetti, and I.M. Herman Mechanisms of normal and tumor-derived angiogenesis Am. J. Physiol. Cell Physiol. 282 2002 C947 C970
71. J.E. Park, M.C. Lenter, R.N. Zimmermann, P. Garin-Chesa, L.J. Old, and W.J. Rettig Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts J. Biol. Chem. 274 1999 36505 36512
72. B.A. Peters, L.A. Diaz, K. Polyak, L. Meszler, K. Romans, E.C. Guinan, J.H. Antin, D. Myerson, S.R. Hamilton, and B. Vogelstein Contribution of bone marrow-derived endothelial cells to human tumor vasculature Nat. Med. 11 2005 261 262
73. O.W. Petersen, L. Ronnov-Jessen, A.R. Howlett, and M.J. Bissell Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells Proc. Natl. Acad. Sci. USA 89 1992 9064 9068
74. K. Pietras, and D. Hanahan A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23 2005 939 952
75. K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.H. Heldin, and A. Ostman Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res. 62 2002 5476 5484
76. K. Pietras, T. Sjoblom, K. Rubin, C.H. Heldin, and A. Ostman PDGF receptors as cancer drug targets Cancer Cell 3 2003 439 443
77. J.W. Pollard Tumour-educated macrophages promote tumour progression and metastasis Nat. Rev. Cancer 4 2004 71 78
78. S.M. Pupa, S. Menard, S. Forti, and E. Tagliabue New insights into the role of extracellular matrix during tumor onset and progression J. Cell. Physiol. 192 2002 259 267
79. S. Rafii, D. Lyden, R. Benezra, K. Hattori, and B. Heissig Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2 2002 826 835
80. I. Rajantie, M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo, and P. Salven Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells Blood 104 2004 2084 2086
81. L. Ryden, B. Linderholm, N.H. Nielsen, S. Emdin, P.E. Jonsson, and G. Landberg Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer Breast Cancer Res. Treat. 82 2003 147 154
82. K.L. Schmeichel, and M.J. Bissell Modeling tissue-specific signaling and organ function in three dimensions J. Cell Sci. 116 2003 2377 2388
83. A.M. Scott, G. Wiseman, S. Welt, A. Adjei, F.T. Lee, W. Hopkins, C.R. Divgi, L.H. Hanson, P. Mitchell, and D.N. Gansen A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer Clin. Cancer Res. 9 2003 1639 1647
84. T. Sethi, R.C. Rintoul, S.M. Moore, A.C. MacKinnon, D. Salter, C. Choo, E.R. Chilvers, I. Dransfield, S.C. Donnelly, R. Strieter, and C. Haslett Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo Nat. Med. 7 1999 186 191
85. K.H. Shain, and W.S. Dalton Cell adhesion is a key determinant in de novo multidrug resistance (MDR): New targets for the prevention of acquired MDR Mol. Cancer Ther. 1 2001 69 78
86. Y. Shaked, F. Bertolini, S. Man, M.S. Rogers, D. Cervi, T. Foutz, K. Rawn, D. Voskas, D.J. Dumont, and Y. Ben-David Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis Cancer Cell 7 2005 101 111
87. S.A. Stacker, C. Caesar, M.E. Baldwin, G.E. Thornton, R.A. Williams, R. Prevo, D.G. Jackson, S.-I. Nishikawa, H. Kubo, and M.G. Achen VEGF-D promotes the metastatic spread of tumor cells via the lymphatics Nat. Med. 7 2001 186 191
88. B. St Croix, C. Rago, V. Velculescu, G. Traverso, K.E. Romans, E. Montgomery, A. Lal, G.J. Riggins, C. Lengauer, B. Vogelstein, and K.W. Kinzler Genes expressed in human tumor endothelium Science 289 2000 1197 1202
89. M.J. Thun, M.M. Namboodiri, and C.W. Heath Jr. Aspirin use and reduced risk of fatal colon cancer N. Engl. J. Med. 325 1991 1593 1596
90. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, and R.K. Jain Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 64 2004 3731 3736
91. J. Vakkila, and M.T. Lotze Inflammation and necrosis promote tumour growth Nat. Rev. Immunol. 4 2004 641 648
92. I. Vlodavsky, O. Goldshmidt, E. Zcharia, R. Atzmon, Z. Rangini-Guatta, M. Elkin, T. Peretz, and Y. Friedmann Mammalian heparanase: Involvement in cancer metastasis, angiogenesis and normal development Semin. Cancer Biol. 12 2002 121 129
93. V.M. Weaver, O.W. Petersen, F. Wang, C.A. Larabell, P. Briand, C. Damsky, and M.J. Bissell Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies J. Cell Biol. 137 1997 231 245
94. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, D.C. Chung, D.V. Sahani, S.P. Kalva, and S.V. Kozin Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2004 145 147
95. F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, L. Xu, D.J. Hicklin, D. Fukumura, and E. di Tomaso Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563
96. C.N. Wrobel, J. Debnath, E. Lin, S. Beausoleil, M.F. Roussel, and J.S. Brugge Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture J. Cell Biol. 165 2004 263 273
97. Y. Yu, A.F. Flint, J.B. Mulliken, J.K. Wu, and J. Bischoff Endothelial progenitor cells in infantile hemangioma Blood 103 2004 1373 1375
98. A. Zlotnik Chemokines in neoplastic progression Semin. Cancer Biol. 14 2004 181 185
99. W. Zou Immunosuppressive networks in the tumor environment and their therapeutic relevance Nat. Rev. Cancer 5 2005 263 274